The pharma company’s $3 billion settlement on improper drug promotions and misbranding charges is the largest yet for the drug industry.
The Department of Justice scored its biggest healthcare fraud settlement yet on July 2 when GlaxoSmithKline agreed to pay $3 billion for promoting off-label uses of its Paxil and Wellbutrin antidepressants and for holding back safety data from the Food and Drug Administration about its Avandia diabetes drug. The previous record-holder was Pfizer, which in 2009 agreed to a $2.3 billion settlement for misbranding and fraudulent promotions. The plea agreement includes a criminal fine of ...
Register for Complete Access (Valid Email Required)
By registering on MeetingsNet now, you'll not only unlock the GlaxoSmithKline Settles for $3 Billion, you'll also gain access to exclusive premium content.